

South Dakota Department of Social Services

Medicaid P&T Committee Meeting
December 1, 2017



Table of Contents

Agenda	2
Minutes	3
PA Update	5
Top 50 Drugs	8
Top 15 Therapeutic Classes	10
Opioid Strategies for Management	11
Duzallo Review	15
Xhance Review	17

**SOUTH DAKOTA
MEDICAID P&T COMMITTEE MEETING
AGENDA**

**December 1, 2017
1:00 – 3:00 PM**

DDN Locations:
Sioux Falls
University Center
Room FADM145
4801 North Career Avenue

Pierre
Capitol Building
DDN Room A
500 East Capitol

Rapid City
Black Hills State University
DDN Room UC113
4300 Cheyenne Boulevard

Call to order

Approval of minutes of previous meeting

PA update

Review of top 15 therapeutic categories/top 50 drugs

Old business

Treatment options for opioid abuse – Tiffany Wolfgang, Division of Behavioral Health
Opioid utilization and strategies for management
Opioid naïve limit

New business

Duzallo
Xhance

Oral presentations and comments by manufacturers' representatives

Next meeting date/adjournment

**South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes**

Friday, September 29, 2017

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baak, MD		Bill Ladwig, RPh	X
Dana Darger, RPh		Kelley Oehlke, PharmD	X
James Engelbrecht, MD	X	Lenny Petrik, PharmD	X
Mikel Holland, MD	X	Timothy Soundy, MD	X
Richard Holm, MD, Chair	X	Mike Jockheck, DSS Staff	X

Administrative Business

The meeting was called to order by Holm at 1:00 PM. The minutes of the March meeting were presented. Soundy requested the minutes to reflect his attendance at the March meeting; March meeting minutes to be amended. Holm made a motion to approve. Oehlke seconded the motion. Motion was approved unanimously.

Introductions

The P&T meeting support transitioned from HID Designs to Optum. Committee members were introduced to the clinical pharmacist from OptumRx.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report for July 2017. There were a total of 2,595 PAs processed in the month of July, with 94.03% of those requests responded to in less than eight hours. There were 2001 requests (77%) received electronically and 594 requests (23%) received via fax.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from 4/1/2017 to 6/30/2017. The top five classes were antipsychotic agents, insulins, respiratory and CNS stimulants, amphetamines, and disease-modifying anti-rheumatic agents. The top 15 therapeutic classes make up 38.39% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 13.28% of total claims.

Opioid Strategies for Management Review

The committee reviewed the report of patients at each morphine equivalent dosage (MED) breakpoint. There were 114 patients taking over 300 MEDs. The committee asked for the geographical zip codes for these utilizations. The top prescribers were two physician assistants and a nurse practitioner. Engelbrecht requested more information regarding the supervising physician and appropriate use of utilization; in addition, the frequency of the physician assistants writing these prescription.

Soundy made a motion to send letters to the top 50 prescribers of opioids for the past year. Ladwig seconded the motion. The motion passed unanimously. Soundy also made a motion for an on-going opioid utilization report at every P&T meeting with the following information listed below. Holland seconded the motion. Motion passed unanimously. Ladwig requested the State to find out how other Medicaid states are managing opioids.

For patients with MED greater than 300:

1. Diagnosis
2. Age/gender
3. Concomitant therapy such as benzodiazepines, etc
4. Number of prescribers
5. Duration of opioid therapy

Review of Codeine and Tramadol Utilization

Committee reviewed the utilization of codeine and tramadol. For patients under 12 years old, there were claims for 10 patients for tramadol utilization; and 880 claims and 758 patients with codeine utilization. There were 384 unique prescribers of codeine for patients less than 12 years old. Soundy made a motion to send letters to these prescribers. Ladwig seconded the motion. Motion passed unanimously.

Dupixent Review

The committee reviewed Dupixent clinical information. Committee clarified the trial of a first-line agent as fluorinated steroid such as e.g. triamcinolone. There was no public comment. Engelbrecht made a motion to place Dupixent on prior authorization. Soundy seconded the motion. The motion was approved unanimously.

Xrylix Kit Review

The committee reviewed Xrylix Kit clinical information. Based on information that Xrylix Kit is not on the CMS covered outpatient drug file due to one component of the kit containing a medical supply item, committee decided not to place on prior authorization. There was no public comment. Engelbrecht made a motion to keep Xrylix Kit as a non-covered item. Ladwig seconded the motion. The motion was approved unanimously.

Zipsor/Zorvolex/Cambia Review

The committee reviewed Zipsor/Zorvolex/Cambia clinical information. There was no public comment. Ladwig made a motion to place Zipsor/Zorvolex/Cambia on prior authorization. Soundy seconded the motion. The motion was approved unanimously. Committee requested utilization information of these products at future meetings.

Optum Overview

OptumRx provided an overview of the administrative support services that will be provided to South Dakota Medicaid. These include PA services, system capabilities, reporting capabilities, and P&T committee support.

Jockcheck provided a brief update on candidates for a new P&T committee member. Committee discussed potential candidates.

Next meeting is scheduled for December 1, 2017. Ladwig made a motion to adjourn. Engelbrecht seconded. The meeting adjourned at 3:30 PM.

Time Ratio

Total PAs	Response Under 8 Hours	Response Over 8 Hours	% Under 8 Hours	% Over 8 Hours
2954	2953	1	99.97%	0.03%

By Form Type

Form Type	Description	Approve	Deny
ADP	Antidepressant	115	169
AFX	Amrix and Fexmid	1	3
AMB	Ambien CR	4	14
ANT	Antihistamines	13	32
APS	Antipsychotic	320	299
ARB	ARBS	2	1
COA	Oral Anticoagulants	13	27
CON	Chronic Constipation Medication	9	9
DAW	Dispense As Written	4	3
DIC	Diclegis	0	1
GLP	GLP-1 Agonists	9	1
GRH	Growth Hormone	4	5
GSM	Genitourinary SMR	2	2
HEP	Hepatitis Meds	2	10
HLM	Head Lice Medication	39	9
LID	Lidoderm	1	70
LYR	Lyrica	8	188
MAX	Max Units Override	56	1055
NAR	Name Brand Narcotics	1	1
NUC	Opioids	7	8
ONF	Onfi	5	0
OPH	Ophthalmic Antihistamines	0	19
OTE	Otezla	1	0
PPI	Proton Pump Inhibitors	27	64
SMR	Skeletal Muscle Relaxants	7	10
STE	Nasal Steroids	8	45
STI	Stimulants	3	13
SUB	Suboxone/Subutex	8	34
TIM	Targeted Immune Modulators	13	14
TOP	Topical Acne Agents	14	90
TRP	Triptans	9	31
ULT	Ultram ER	1	3
VIB	Viberzi	1	0
XIF	Xifaxan	3	12
XOI	Xanthine Oxidase Inhibitor	1	0
XOL	Xolair	1	0
Totals		712	2242

By Request Type

10/01/17 – 10/31/17	# of Requests	Electronic Requests		Faxed Requests	
		#	%	#	%
Prior Authorizations					
Antidepressant	284	211	74%	73	26%
Amrix and Fexmid	4	3	75%	1	25%
Ambien CR	18	14	78%	4	22%
Antihistamines	45	31	69%	14	31%
Antipsychotic	619	399	64%	220	36%
ARBS	3	3	100%	0	0%
Oral Anticoagulants	40	32	80%	8	20%
Chronic Constipation Medications	18	0	0%	18	100%
Dispense As Written	7	0	0%	7	100%
Diclegis	1	1	100%	0	0%
GLP-1 Agonists	10	0	0%	10	100%
Growth Hormone	9	4	44%	5	56%
Genitourinary SMR	4	2	50%	2	50%
Hepatitis Meds	12	0	0%	12	100%
Head Lice Medication	48	0	0%	48	100%
Lidoderm	71	60	85%	11	15%
Lyrica	196	153	78%	43	22%
Max Units Override	1111	1016	91%	95	9%
Name Brand Narcotics	2	0	0%	2	100%
Opioids	15	8	53%	7	47%
Onfi	5	0	0%	5	100%
Ophthalmic Antihistamines	19	15	79%	4	21%
Otezla	1	0	0%	1	100%
Proton Pump Inhibitors	91	70	77%	21	23%
Skeletal Muscle Relaxants	17	17	100%	0	0%
Nasal Steroids	53	47	89%	6	11%
Stimulants	16	12	75%	4	25%
Suboxone/Subutex	42	30	71%	12	29%
Targeted Immune Modulators	27	13	48%	14	52%
Topical Acne Agents	104	80	77%	24	23%
Triptans	40	29	73%	11	28%
Ultram ER	4	4	100%	0	0%
Viberzi	1	0	0%	1	100%
Xifaxan	15	10	67%	5	33%
Xanthine Oxidase Inhibitor	1	1	100%	0	0%
Xolair	1	0	0%	1	100%
Prior Authorization Totals	2954	2265	77%	689	23%

Electronic PAs (Unique)

10/01/17 – 10/31/17	# Unique	# Unique	# Unique	Unique	Approval	Total
	Approved	Denied	Incomplete	Total	%	Transactions
Prior Authorizations:						
Antidepressant	71	134	0	205	34.60%	211
Amrix and Fexmid	1	2	0	3	33.30%	3
Ambien CR	1	12	0	13	7.70%	14
Antihistamines	6	25	0	31	19.40%	31
Antipsychotic	144	242	0	386	37.30%	399
ARBS	2	1	0	3	66.70%	3
Oral Anticoagulants	7	24	0	31	22.60%	32
Diclegis	0	1	0	1	0.00%	1
Growth Hormone	0	4	0	4	0.00%	4
Genitourinary SMR	1	1	0	2	50.00%	2
Lidoderm	0	57	0	57	0.00%	60
Lyrica	2	131	0	133	1.50%	153
Max Units Override	5	965	0	970	0.50%	1016
Opioids	4	4	0	8	50.00%	8
Ophthalmic Antihistamines	0	15	0	15	0.00%	15
Proton Pump Inhibitors	14	50	0	64	21.90%	70
Skeletal Muscle Relaxants	7	10	0	17	41.20%	17
Nasal Steroids	5	41	0	46	10.90%	47
Stimulants	0	9	0	9	0.00%	12
Suboxone/Subutex	1	26	0	27	3.70%	30
Targeted Immune Modulators	3	8	0	11	27.30%	13
Topical Acne Agents	7	70	0	77	9.10%	80
Triptans	5	23	0	28	17.90%	29
Ultram ER	1	3	0	4	25.00%	4
Xifaxan	0	8	0	8	0.00%	10
Xanthine Oxidase Inhibitor	1	0	0	1	100.00%	1
TOTALS	288	1866	0	2154	13.40%	2265

TOP 50 DRUGS BASED ON NUMBER OF CLAIMS FROM 07/01/2017 - 09/30/2017

Drug	AHFS Therapeutic Class	Rx	Paid	Paid/Rx	% Total Claims
AMOXICILLIN	PENICILLINS	3,996	\$ 33,209.81	\$ 8.31	2.32%
HYDROCODONE-ACETAMINOPHEN	OPIATE AGONISTS	3,897	\$ 67,230.81	\$ 17.25	2.26%
CETIRIZINE HCL	SECOND GENERATION ANTIHISTAMINES	3,736	\$ 26,752.42	\$ 7.16	2.17%
FLUOXETINE HCL	ANTIDEPRESSANTS	3,271	\$ 36,434.55	\$ 11.14	1.90%
OMEPRAZOLE	PROTON-PUMP INHIBITORS	3,264	\$ 28,270.30	\$ 8.66	1.89%
METHYLPHENIDATE ER	RESPIRATORY AND CNS STIMULANTS	3,080	\$ 651,260.90	\$ 211.45	1.79%
MONTELUKAST SODIUM	LEUKOTRIENE MODIFIERS	3,074	\$ 41,710.18	\$ 13.57	1.78%
SERTRALINE HCL	ANTIDEPRESSANTS	2,825	\$ 20,681.65	\$ 7.32	1.64%
VYVANSE	AMPHETAMINES	2,809	\$ 729,040.82	\$ 259.54	1.63%
LEVOTHYROXINE SODIUM	THYROID AGENTS	2,736	\$ 42,517.55	\$ 15.54	1.59%
GABAPENTIN	ANTICONVULSANTS, MISCELLANEOUS	2,460	\$ 35,450.53	\$ 14.41	1.43%
TRAZODONE HCL	ANTIDEPRESSANTS	2,278	\$ 14,211.09	\$ 6.24	1.32%
LISINAPRIL	ANGIOTENSIN-CONVERTING ENZYME INHIBITORS	2,078	\$ 11,039.03	\$ 5.31	1.21%
TRAMADOL HCL	OPIATE AGONISTS	1,917	\$ 15,432.10	\$ 8.05	1.11%
GUANFACINE HCL ER	CENTRAL NERVOUS SYSTEM AGENTS, MISC.	1,912	\$ 47,906.76	\$ 25.06	1.11%
LORATADINE	SECOND GENERATION ANTIHISTAMINES	1,882	\$ 10,775.48	\$ 5.73	1.09%
VENTOLIN HFA	BETA-ADRENERGIC AGONISTS	1,735	\$ 101,903.95	\$ 58.73	1.01%
AZITHROMYCIN	MACROLIDES	1,721	\$ 23,022.96	\$ 13.38	1.00%
CLONIDINE HCL	CENTRAL ALPHA-AGONISTS	1,708	\$ 11,056.49	\$ 6.47	0.99%
CEPHALEXIN	CEPHALOSPORINS	1,656	\$ 25,967.53	\$ 15.68	0.96%
FLUTICASON PROPRIONATE	CORTICOSTEROIDS (EENT)	1,647	\$ 12,626.00	\$ 7.67	0.96%
PROAIR HFA	BETA-ADRENERGIC AGONISTS	1,582	\$ 99,629.29	\$ 62.98	0.92%
DEXTRAMPHETAMINE-AMPHET ER	AMPHETAMINES	1,570	\$ 177,509.29	\$ 113.06	0.91%
CLONAZEPAM	BENZODIAZEPINES (ANTICONVULSANTS)	1,560	\$ 11,944.99	\$ 7.66	0.90%
POLYETHYLENE GLYCOL 3350	CATHARTICS AND LAXATIVES	1,415	\$ 37,230.86	\$ 26.31	0.82%
ALBUTEROL SULFATE	BETA-ADRENERGIC AGONISTS	1,412	\$ 24,531.02	\$ 17.37	0.82%
ESCITALOPRAM OXALATE	ANTIDEPRESSANTS	1,401	\$ 14,120.41	\$ 10.08	0.81%
METFORMIN HCL	BIGUANIDES	1,387	\$ 9,138.38	\$ 6.59	0.80%
SULFAMETHOXAZOLE-TRIMETHOPRIM	SULFONAMIDES (SYSTEMIC)	1,380	\$ 25,412.93	\$ 18.42	0.80%
PREDNISONE	ADRENALS	1,333	\$ 10,715.02	\$ 8.04	0.77%
ARIPIRAZOLE	ANTIPSYCHOTIC AGENTS	1,296	\$ 61,787.74	\$ 47.68	0.75%
LAMOTRIGINE	ANTICONVULSANTS, MISCELLANEOUS	1,293	\$ 15,655.20	\$ 12.11	0.75%
ATORVASTATIN CALCIUM	HMG-COA REDUCTASE INHIBITORS	1,273	\$ 12,951.03	\$ 10.17	0.74%
IBUPROFEN	NONSTEROIDAL ANTI-INFLAMMATORY AGENTS	1,252	\$ 9,186.40	\$ 7.34	0.73%
RISPERIDONE	ANTIPSYCHOTIC AGENTS	1,251	\$ 13,167.68	\$ 10.53	0.73%
TRIAMCINOLONE ACETONIDE	ANTI-INFLAMMATORY AGENTS (SKIN, MUCOUS)	1,188	\$ 14,213.46	\$ 11.96	0.69%
QUETIAPINE FUMARATE	ANTIPSYCHOTIC AGENTS	1,164	\$ 12,409.03	\$ 10.66	0.68%
LORAZEPAM	BENZODIAZEPINES (ANXIOLYTIC, SEDATIV/HYP)	1,127	\$ 7,415.12	\$ 6.58	0.65%
CITALOPRAM HBR	ANTIDEPRESSANTS	1,110	\$ 6,162.21	\$ 5.55	0.64%
AMOXICILLIN-CLAVULANATE POTASS	PENICILLINS	1,102	\$ 19,919.31	\$ 18.08	0.64%
CYCLOBENZAPRINE HCL	CENTRALLY ACTING SKELETAL MUSCLE RELAXNT	1,083	\$ 6,873.16	\$ 6.35	0.63%
MUPIROCIN	ANTIBACTERIALS (SKIN, MUCOUS MEMBRANE)	1,078	\$ 36,103.68	\$ 33.49	0.63%
LEVETIRACETAM	ANTICONVULSANTS, MISCELLANEOUS	1,062	\$ 20,739.95	\$ 19.53	0.62%
BUPROPION XL	ANTIDEPRESSANTS	1,041	\$ 19,905.71	\$ 19.12	0.60%
DEXMETHYLPHENIDATE HCL ER	RESPIRATORY AND CNS STIMULANTS	1,040	\$ 203,794.03	\$ 195.96	0.60%
VITAMIN D2	VITAMIN D	1,030	\$ 6,038.31	\$ 5.86	0.60%
ONDANSETRON ODT	5-HT3 RECEPTOR ANTAGONISTS	996	\$ 14,104.98	\$ 14.16	0.58%
MIRTAZAPINE	ANTIDEPRESSANTS	973	\$ 12,009.89	\$ 12.34	0.56%
RANITIDINE HCL	HISTAMINE H2-ANTAGONISTS	972	\$ 7,880.15	\$ 8.11	0.56%
TOPIRAMATE	ANTICONVULSANTS, MISCELLANEOUS	971	\$ 10,784.52	\$ 11.11	0.56%
TOTAL TOP 25		89,024	\$ 2,907,834.66	\$ 32.66	51.63%

Total Rx Claims From 07/01/2017 - 09/30/2017	172,431
---	---------

TOP 50 DRUGS BASED ON TOTAL CLAIMS COST FROM 07/01/2017 - 09/30/2017

Drug	AHFS Therapeutic Class	Rx	Paid	Paid/Rx	% Total Claims
VYVANSE	AMPHETAMINES	2,809	\$ 729,040.82	\$ 259.54	1.63%
METHYLPHENIDATE ER	RESPIRATORY AND CNS STIMULANTS	3,080	\$ 651,260.90	\$ 211.45	1.79%
LATUDA	ANTIPSYCHOTIC AGENTS	362	\$ 426,659.31	\$ 1,178.62	0.21%
HUMIRA PEN	DISEASE-MODIFYING ANTIRHEUMATIC AGENTS	65	\$ 322,066.17	\$ 4,954.86	0.04%
INVEGA SUSTENNA	ANTIPSYCHOTIC AGENTS	139	\$ 275,160.74	\$ 1,979.57	0.08%
ENBREL	DISEASE-MODIFYING ANTIRHEUMATIC AGENTS	60	\$ 252,583.41	\$ 4,209.72	0.03%
NOVOLOG FLEXPEN	INSULINS	453	\$ 249,289.58	\$ 550.31	0.26%
LYRICA	ANTICONVULSANTS, MISCELLANEOUS	480	\$ 241,592.17	\$ 503.32	0.28%
ONFI	BENZODIAZEPINES (ANTICONVULSANTS)	194	\$ 237,086.97	\$ 1,222.10	0.11%
EPCLUSA	HCV ANTIVIRALS	9	\$ 234,174.72	\$ 26,019.41	0.01%
DEXMETHYLPHENIDATE HCL ER	RESPIRATORY AND CNS STIMULANTS	1,040	\$ 203,794.03	\$ 195.96	0.60%
ADVAIR DISKUS	CORTICOSTEROIDS (RESPIRATORY TRACT)	491	\$ 186,714.52	\$ 380.27	0.28%
PULMOZYME	MUCOLYTIC AGENTS	52	\$ 186,293.60	\$ 3,582.57	0.03%
NOVOLOG	INSULINS	367	\$ 186,290.82	\$ 507.60	0.21%
DEXTROAMPHETAMINE-AMPHET ER	AMPHETAMINES	1,570	\$ 177,509.29	\$ 113.06	0.91%
KALYDECO	CYSTIC FIBROSIS (CFTR) POTENTIATORS	7	\$ 174,653.82	\$ 24,950.55	0.00%
FLOVENT HFA	CORTICOSTEROIDS (RESPIRATORY TRACT)	726	\$ 166,005.00	\$ 228.66	0.42%
LANTUS SOLOSTAR	INSULINS	434	\$ 164,823.35	\$ 379.78	0.25%
STELARA	SKIN AND MUCOUS MEMBRANE AGENTS, MISC.	9	\$ 135,925.96	\$ 15,102.88	0.01%
PREVACID	PROTON-PUMP INHIBITORS	274	\$ 134,031.41	\$ 489.17	0.16%
ORKAMBI	CYSTIC FIBROSIS (CFTR) POTENTIATORS	6	\$ 127,944.45	\$ 21,324.08	0.00%
LEVEMIR FLEXTOUCH	INSULINS	270	\$ 127,473.86	\$ 472.13	0.16%
RECOMBINATE	HEMOSTATICS	4	\$ 126,158.31	\$ 31,539.58	0.00%
COPAXONE	IMMUNOMODULATORY AGENTS	18	\$ 112,311.38	\$ 6,239.52	0.01%
GATTEX	GI DRUGS, MISCELLANEOUS	3	\$ 110,441.47	\$ 36,813.82	0.00%
VIMPAT	ANTICONVULSANTS, MISCELLANEOUS	155	\$ 108,639.29	\$ 700.90	0.09%
ADVATE	HEMOSTATICS	6	\$ 105,678.71	\$ 17,613.12	0.00%
GENOTROPIN	PITUITARY	24	\$ 103,273.77	\$ 4,303.07	0.01%
INVEGA TRINZA	ANTIPSYCHOTIC AGENTS	17	\$ 102,375.10	\$ 6,022.06	0.01%
VENTOLIN HFA	BETA-ADRENERGIC AGONISTS	1,735	\$ 101,903.95	\$ 58.73	1.01%
JANUVIA	DIPEPTIDYL PEPTIDASE-4(DPP-4) INHIBITORS	253	\$ 99,848.53	\$ 394.66	0.15%
PROAIR HFA	BETA-ADRENERGIC AGONISTS	1,582	\$ 99,629.29	\$ 62.98	0.92%
HARVONI	HCV ANTIVIRALS	3	\$ 98,661.30	\$ 32,887.10	0.00%
NORDITROPIN FLEXPRO	PITUITARY	39	\$ 97,734.36	\$ 2,506.01	0.02%
BANZEL	ANTICONVULSANTS, MISCELLANEOUS	53	\$ 94,830.17	\$ 1,789.25	0.03%
ARISTADA	ANTIPSYCHOTIC AGENTS	43	\$ 91,677.99	\$ 2,132.05	0.02%
EPINEPHRINE	ALPHA- AND BETA-ADRENERGIC AGONISTS	246	\$ 83,720.73	\$ 340.33	0.14%
CREON	DIGESTANTS	58	\$ 83,515.56	\$ 1,439.92	0.03%
HUMIRA	DISEASE-MODIFYING ANTIRHEUMATIC AGENTS	13	\$ 83,487.07	\$ 6,422.08	0.01%
LANTUS	INSULINS	192	\$ 81,701.29	\$ 425.53	0.11%
BUDESONIDE	CORTICOSTEROIDS (RESPIRATORY TRACT)	288	\$ 79,847.23	\$ 277.25	0.17%
PROMACTA	HEMATOPOIETIC AGENTS	9	\$ 79,046.50	\$ 8,782.94	0.01%
XOLAIR	RESPIRATORY TRACT AGENTS, MISCELLANEOUS	25	\$ 77,166.39	\$ 3,086.66	0.01%
SYMBICORT	CORTICOSTEROIDS (RESPIRATORY TRACT)	238	\$ 73,016.11	\$ 306.79	0.14%
ATOMOXETINE HCL	CENTRAL NERVOUS SYSTEM AGENTS, MISC.	666	\$ 72,405.71	\$ 108.72	0.39%
REVLIMID	ANTINEOPLASTIC AGENTS	4	\$ 70,460.12	\$ 17,615.03	0.00%
IMBRUVICA	ANTINEOPLASTIC AGENTS	6	\$ 69,555.24	\$ 11,592.54	0.00%
REXULTI	ANTIPSYCHOTIC AGENTS	67	\$ 69,410.01	\$ 1,035.97	0.04%
OXYCONTIN	OPIATE AGONISTS	196	\$ 69,185.72	\$ 352.99	0.11%
IBRANCE	ANTINEOPLASTIC AGENTS	6	\$ 68,154.00	\$ 11,359.00	0.00%
TOTAL TOP 25		18,846	\$ 8,104,210.20	\$ 430.02	10.93%

Total Rx Claims From 07/01/2017 - 09/30/2017	172,431
---	---------


**SOUTH DAKOTA MEDICAID
Cost Management Analysis**

TOP 15 THERAPEUTIC CLASSES BY TOTAL COST OF CLAIMS FROM 07/01/2017 - 09/30/2017

AHFS Therapeutic Class	Rx	Paid	Paid/Rx	% Total Claims
ANTIPSYCHOTIC AGENTS	6,083	\$ 1,359,998.29	\$ 223.57	3.53%
INSULINS	2,351	\$ 1,144,739.49	\$ 486.92	1.36%
RESPIRATORY AND CNS STIMULANTS	5,698	\$ 1,038,743.90	\$ 182.30	3.30%
AMPHETAMINES	5,324	\$ 949,869.82	\$ 178.41	3.09%
ANTICONVULSANTS, MISCELLANEOUS	8,878	\$ 860,468.78	\$ 96.92	5.15%
DISEASE-MODIFYING ANTIRHEUMATIC AGENTS	212	\$ 837,821.51	\$ 3,951.99	0.12%
CORTICOSTEROIDS (RESPIRATORY TRACT)	2,563	\$ 721,327.95	\$ 281.44	1.49%
ANTINEOPLASTIC AGENTS	284	\$ 478,292.38	\$ 1,684.13	0.16%
ANTIRETROVIRALS	193	\$ 334,040.34	\$ 1,730.78	0.11%
HCV ANTIVIRALS	12	\$ 332,836.02	\$ 27,736.34	0.01%
IMMUNOMODULATORY AGENTS	43	\$ 326,384.91	\$ 7,590.35	0.02%
HEMOSTATICS	25	\$ 310,804.19	\$ 12,432.17	0.01%
CYSTIC FIBROSIS (CFTR) POTENTIATORS	13	\$ 302,598.27	\$ 23,276.79	0.01%
BETA-ADRENERGIC AGONISTS	5,338	\$ 301,068.43	\$ 56.40	3.10%
OPIATE AGONISTS	9,018	\$ 297,718.31	\$ 33.01	5.23%
TOTAL TOP 15	46,035	\$ 9,596,712.59	\$ 208.47	26.70%

Total Rx Claims From 07/01/2017 - 09/30/2017	172,431
---	---------

**Top 15 Therapeutic Classes
Based on Total Cost of Claims**



Opioid Utilization Summary

Top 10 recipients with greater than 300 MED for year 2017

Recipients' age ranged from 31 years to 61 years old

Age Range

30-39	4 females
40-49	1 male, 1 female
50-59	1 male, 1 female
60-69	1 male, 1 female

Diagnosis and Utilization Summary:

1. 31 year old female: fibromyalgia, pain in left & right foot, pain in left & right knee, pain in left & right hip, chronic pain syndrome, systemic lupus erythematosus, other chronic pain
 - Number of prescribers: ~1
 - Opioids & concomitant therapy: oxycodone hcl 20 mg, oxycodone hcl 30 mg
 - One month snapshot:
 - 9/28/17 oxycodone 20 mg, qty 540/30 days
 - 9/28/17 oxycodone 30 mg, qty 540/30 days
2. 49 year old female: anxiety disorder, major depressive disorder, pressure ulcer of right buttock, drug induced constipation, other chronic pain, type 2 DM, UTI, sepsis, right lower quadrant pain
 - Number of prescribers: ~ 4
 - Opioids & concomitant therapy: fentanyl 25 mcg, fentanyl 50 mcg, fentanyl 100 mcg, oxycodone hcl 10 mg, oxycodone hcl 20 mg, methadone 5 mg, gabapentin 300 mg, gabapentin 600 mg, lorazepam 1 mg, buspirone 7.5 mg
 - One month snapshot:
 - 10/17/17 fentanyl 100 mcg, qty 5/15 days
 - 10/10/17 oxycodone 30 mg, qty 30/5 days
 - 10/9/17 methadone 5 mg, qty 49/14 days
 - 10/8/17 methadone 5 mg, qty 3/1 day
 - 10/2/17 oxycodone 20 mg, qty 60/10 days
 - 10/2/17 fentanyl 100 mcg, qty 5/15 days
 - 10/2/17 fentanyl 25 mcg, qty 5/15 days
 - 10/2/17 fentanyl 50 mcg, qty 6/2 days
3. 39 year old female: pain in unspecified hip, constipation, Hallervorden-Spatz disease, pain in left & right foot, acquired keratosis, generalized atherosclerosis
 - Number of prescribers: ~2
 - Opioids & concomitant therapy: fentanyl 100 mcg, fentanyl 50 mcg, tramadol 50 mg, baclofen 10 mg,

- One month snapshot:
 - 10/23/17 fentanyl 100 mcg, qty 5/15 days
 - 10/23/17 fentanyl 50 mcg, qty 5/15 days
 - 10/23/17 tramadol 50 mg, qty 60/15 days
 - 10/11/17 tramadol 50 mg, qty 60/15 days
 - 10/10/17 fentanyl 50 mcg, qty 5/15 days
 - 10/4/17 fentanyl 100 mcg, qty 5/15 days
 - 10/4/17 baclofen 10 mg, qty 90/30 days
 - 10/2/17 tramadol 50 mg, qty 60/15 days
4. 33 year old female: right lower quadrant pain, hyperglycemia, pelvic & perineal pain, ovarian cyst, systemic inflammatory response, unspecified abdominal pain, opioid dependence uncomplicated, Type 1 DM, sepsis, enterocolitis, epigastric pain, endometriosis, other chronic pain, polycystic ovarian syndrome, nicotine dependence, dysuria, other muscle spasm, other ovarian cyst, other muscle spasm, pain in left shoulder, chronic pain syndrome, gastroparesis, major depressive disorder, dysphagia, gastroparesis, GERD, Type 2 DM, anxiety, low back pain, pain in right finger, pain in left & right foot, pain in left and right hand, cervicalgia, myalgia
- Number of prescribers: ~5
 - Opioids & concomitant therapy: hydrocodone/APAP 10-325 mg, hydromorphone 4 mg, tizanidine 4 mg
 - One month snapshot:
 - 10/25/17 hydrocodone/APAP 10-325 mg, qty 112/14 days
 - 10/25/17 hydromorphone 4 mg, qty 60/14 days
 - 10/24/17 hydrocodone/APAP 10-325 mg, qty 10/1 day
 - 10/9/17 hydromorphone 4 mg, qty 60/14 days
 - 10/9/17 hydrocodone/APAP 10-325 mg, qty 130/13 days
 - 9/26/17 hydromorphone 4 mg, qty 60/14 days
 - 9/25/17 hydrocodone/APAP 10-325 mg, qty 128/14 days
 - 9/25/17 tizanidine 4 mg, qty 90/days
5. 54 year old male: lumbago with sciatica, anxiety disorder, panic disorder, long term use of opioids, low back pain, other chronic pain
- Number of prescribers: ~3
 - Opioids & concomitant therapy: hydromorphone 4 mg, morphine sulfate 15 mg, clonazepam 0.5 mg,
 - One month snapshot:
 - 10/18/17 hydromorphone 4 mg, qty 126/10 days
 - 10/18/17 morphine sulfate 15 mg, qty 84/14 days
 - 10/18/17 morphine sulfate 15 mg, qty 112/14 days
 - 10/14/17 clonazepam 0.5 mg, qty 90/30 days
 - 10/4/17 morphine sulfate 15 mg, qty 112/14 days
 - 10/4/17 morphine sulfate 15mg, qty 84/14 days
 - 10/4/17 hydromorphone 4 mg, qty 126/14 days

6. 39 year old female: herpesviral vulvovaginitis, dysuria, low back pain, anxiety disorder, Type 1 DM
 - Number of prescribers: ~3
 - Opioids & concomitant therapy: oxycodone hcl 10 mg, cyclobenzaprine 10 mg, diazepam 5 mg, Oxycontin 10 mg, oxycodone hcl 10 mg, trazdone 50 mg
 - One month snapshot:
 - 10/25/17 oxycodone 10 mg, qty 120/10 days
 - 10/23/17 diazepam 5 mg, qty 60/20 days
 - 10/12/17 Oxycontin 10 mg, qty 60/30 days
 - 10/12/17 oxycodone hcl 10 mg, qty 120/10 days
 - 10/4/17 oxycodone hcl 10 mg, qty 15/7 days
 - 10/4/17 cyclobenzaprine 10mg, qty 30/10 days
 - 10/4/17 diazepam 5 mg, qty 60/20 days
 - 10/3/17 trazdone 50 mg, qty 30/30 days

7. 61 year old male: amyotrophic lateral sclerosis, other general symptoms, salmonella enteritis, dependence on respirator, in-growing nail
 - Number of prescribers: ~1
 - Opioids & concomitant therapy: fentanyl 100 mcg, fentanyl 50 mcg, oxycodone hcl 5 mg/5 ml
 - One month snapshot:
 - 10/16/17 fentanyl 100 mcg, qty 10/30 days
 - 10/16/17 fentanyl 50 mcg, qty 10/30 days
 - 10/9/17 oxycodone hcl 5 mg/5 ml, qty 1000/16 days

8. 49 year old male: personal history of transient ischemic attack (TIA), low back pain, primary hypertension, other chronic pain, hyperlipidemia, Type 2 DM, other long term drug therapy
 - Number of prescribers: ~2
 - Opioids & concomitant therapy: oxycodone hcl 10 mg, oxycodone hcl 5 mg, fentanyl 75 mcg, hydrocodone/APAP 7.5-325 mg, hydrocodone/IBU 7.5-200 mg
 - One month snapshot:
 - 10/20/17 fentanyl 75 mcg, qty 5/15 days
 - 10/17/17 oxycodone hcl 10 mg, qty 50/7 days
 - 10/11/17 oxycodone hcl 5 mg, qty 50/6 days
 - 10/6/17 fentanyl 75 mcg, qty 5/15 days
 - 10/5/17 hydrocodone/APAP 7.5-325 mg, qty 50/7 days

9. 54 year old female: pain in left shoulder, other chronic pain, primary hypertension, Type 2 DM, unspecified abdominal pain, cervicalgia, disease of intestines, anxiety disorder, thoracic and cervical spondylosis, pain in arm, pain in shoulder, dizziness and giddiness, spinal stenosis, other cervical disc degeneration, BMI 28, headache, radiculopathy cervical region, personal history of colonic polyps, long term use of insulin, major depressive disorder, polyneuropathy, pain in left and right leg, pain in right shoulder, arthrodesis status, presence of left artificial knee joint, unspecified fall, primary osteoarthritis, other problems related to life, unspecified fall, unspecified injury of left wrist and elbow, strain of

unspecified muscle, pain in left ankle and joints, presbyopia, unspecified astigmatism, myopia, Type 1 DM

- Number of prescribers: ~3
- Opioids & concomitant therapy: oxycodone/APAP 10-325 mg, alprazolam 1 mg, hydrocodone/APAP 10-325 mg, tizanidine 4 mg, oxycodone hcl 15 mg, oxycodone hcl 10 mg, hydromorphone 4 mg, gabapentin 600 mg, gabapentin 400 mg
- One month snapshot:
 - 10/20/17 oxycodone/APAP 10-325 mg, qty 60/10 days
 - 10/20/17 alprazolam 1 mg, qty 20/10 days
 - 10/20/17 tizanidine 4 mg, qty 15/5 days
 - 10/16/17 oxycodone/APAP 10-325 mg, qty 60/12 days
 - 10/13/17 oxycodone/APAP 10-325 mg, qty 20/4 days
 - 10/13/17 alprazolam 1 mg, qty 20/10 days
 - 10/9/17 gabapentin 600 mg, qty 90/days
 - 10/9/17 hydrocodone/APAP 10-325 mg, qty 40/7 days
 - 10/6/17 alprazolam 1 mg, qty 20/10 days
 - 10/6/17 oxycodone hcl 15 mg, qty 60/7 days
 - 10/2/17 hydromorphone 4 mg, qty 30/8 days
 - 9/29/17 oxycodone hcl 15 mg, qty 60/7 days
 - 9/29/17 alprazolam 1 mg, qty 20/10 days
 - 9/27/17 tizanidine 4 mg, qty 15/10 days
 - 9/27/17 gabapentin 400 mg, qty 90/days
 - 9/27/17 hydromorphone 4 mg, qty 30/8 days
 - 9/22/17 oxycodone hcl 15 mg, qty 60/7 days
 - 9/22/17 alprazolam 1 mg, qty 20/10 days
 - 9/19/17 hydromorphone 4 mg, qty 30/8 days

10. 60 year old female: spinal stenosis lumbar region, tracheostomy status, laceration without foreign body left foot, anemia, primary hypertension, Type 2 DM, unspecified illness, cramp and spasm, spinal stenosis, other fatigue, headache, long term current use of insulin, dorsalgia, unspecified abdominal hernia, unspecified asthma uncomplicated, other long term current drug use, non-pressure chronic ulcer of unspecified heel

- Number of prescribers: ~2
- Opioids & concomitant therapy: lorazepam 2 mg, morphine sulfate 30 mg, ibuprofen 800 mg, gabapentin 300 mg
- One month snapshot:
 - 10/7/17 lorazepam 2 mg, qty 90/30 days
 - 10/7/17 morphine sulfate 30 mg, qty 360/30 days
 - 10/7/17 morphine sulfate 30 mg, qty 120/30 days
 - 10/4/17 ibuprofen 800 mg, qty 90/days

PRODUCT DETAILS OF DUZALLO (lesinurad/allopurinol)

A combination drug containing lesinurad, a URAT1 (uric acid transporter 1) inhibitor and allopurinol (xanthine oxidase inhibitor). Lesinurad works by helping the kidney excrete uric acid by inhibiting the function of transporter proteins involved in uric acid reabsorption in the kidney. Allopurinol reduces the production of uric acid.

INDICATIONS AND USE

Treatment of hyperuricemia associated with gout in adults not achieving target serum uric acid levels with allopurinol alone.

DOSAGE AND ADMINISTRATION

Recommended dose is 1 tablet (containing lesinurad 200 mg; allopurinol 200 mg or 300 mg) once daily for patients who have not achieved target serum uric acid on allopurinol 300 mg/day or more. Duzallo is not recommended for patients taking an allopurinol dose of less than 300 mg/day or for patients with asymptomatic hyperuricemia.

DOSAGE FORMS AND STRENGTHS

Tablets:

- 200 mg lesinurad/200 mg allopurinol
- 200 mg lesinurad/300 mg allopurinol

CONTRAINDICATIONS

Duzalla carries a boxed warning for risk of acute renal failure. It should not be initiated in patients with an estimated creatinine clearance (eCrCl) less than 45mL/min. Duzallo is contraindicated in patients with the following conditions:

- severe renal impairment, end stage renal disease, kidney transplant recipients, or patients receiving dialysis
- a known hypersensitivity to allopurinol, including previous occurrence of skin rash or serious rash
- tumor lysis syndrome (TLS) or Lesch-Nyhan syndrome, where the rate of uric acid formation is greatly increased

WARNINGS AND PRECAUTIONS

- *Renal Events*
- *Skin rash and hypersensitivity*
- *Hepatotoxicity*
- *Cardiovascular events:* major adverse cardiovascular events were observed with lesinurad; a causal relationship has not been established
- *Bone marrow suppression:* bone marrow depression affecting one or more cell lines have been reported with allopurinol

ADVERSE REACTIONS

The most common adverse reactions for lesinurad in combination with a xanthine oxidase inhibitor and more frequently than on xanthine oxidase inhibitor alone were headache, influenza, blood creatinine increased, and gastroesophageal reflux disease. The most frequently reported adverse reaction for allopurinol is skin rash.

DRUG INTERACTIONS

Mercaptopurine or Azathioprine: Reduce mercaptopurine or azathioprine dose to approximately one-third to one-fourth of the usual dose and closely monitor for therapeutic response and the appearance of toxicity.

Coumarin Anticoagulants: Carefully monitor prothrombin time.

Moderate Cytochrome P450 2C9 (CYP2C9) Inhibitors: Use DUZALLO with caution.

CYP3A Substrates: Monitor for efficacy of the CYP3A substrate.

USE IN SPECIAL POPULATIONS

Renal impairment: Not recommended for patients with eCrCl below 45 mL/min.

Hepatic impairment: Not recommended for patients with severe hepatic impairment.

CLASS OVERVIEW OF ANTI-GOUT AGENTS

Medication	Manufacturer	Availability	SDM
colchicine/probenecid	Various	Generic: 0.5mg/500mg tablet	
Colcrys (colchicine)	Takeda	Brand: 0.6mg tablet	
Krystexxa (pegloticase)	Crealta	Brand: 8mg IV infusion	
Mitigare (colchicine)	Hikma Americas	Brand: 0.6mg capsule	
Uloric (febuxostat)	AstraZeneca	Brand 40mg, 80mg tablets	PA
Zurampic (lesinurad)	AstraZeneca	Brand 200mg tablet	P&T 6/2016
Zyloprim (allopurinol)	Sebela Pharmaceuticals	Brand/Generic: 100mg, 300mg tablets	
Duzallo (lesinurad/allopurinol)	Ironwood Pharmaceuticals	Brand: 200mg/200mg, 200mg/300 mg	P&T 12/2017

References

1. Duzallo [package insert]. Cambridge, MA: Ironwood Pharmaceuticals, Inc; August 2017.
2. Clinical Pharmacology [online database]. Tampa, FL: Elsevier / Gold Standard, Inc. 2017. Available at www.clinicalpharmacology-ip.com. Accessed on November, 2017.
3. Lexicomp Online, Hudson, Ohio; Lexi-Comp, Inc.; 2017. Available at <http://online.lexi.com>. Accessed on November 2017
4. Becker MA. UptoDate Web site. Clinical Manifestations of Gout. http://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-ofgout?source=search_result&search=gout&selectedTitle=2%7E150. Accessed November 2017.

PRODUCT DETAILS OF XHANCE (fluticasone propionate)

Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity.

INDICATIONS AND USE

Corticosteroid indicated for the treatment of nasal polyps in patients 18 years of age or older.

DOSAGE AND ADMINISTRATION

One spray per nostril twice daily (total daily dose of 372 mcg). Two sprays per nostril twice daily may also be effective in some patients (total daily dose of 744 mcg).

DOSAGE FORMS AND STRENGTH

- 93mcg/actuation nasal spray

CONTRAINDICATIONS

Hypersensitivity to any ingredient in Xhance.

WARNINGS AND PRECAUTIONS

- Local nasal effects: epistaxis, erosion, ulceration, septal perforation, *Candida albicans* infection, and impaired wound healing
- Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma.
- Close monitoring for glaucoma and cataracts is warranted.

ADVERSE REACTIONS

The most common adverse reactions are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS

Strong cytochrome P450 3Q4 inhibitors: Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIAL POPULATIONS

XHANCE was not studied in any special populations, and no gender-specific pharmacokinetic data have been obtained.

CLASS OVERVIEW OF INTRANASAL CORTICOSTEROIDS

Medication	Manufacturer	Info	SDM
Beconase AQ (beclomethasone dipropionate monohydrate)	GlaxoSmithKline	FDA-approved management of nasal polyps	ST
Dymista (azelastine HCl–fluticasone propionate)	Meda Pharmaceuticals		ST
Flonase Allergy Relief (fluticasone propionate)	GlaxoSmithKline	OTC	ST
Flonase SensiMist Allergy Relief (fluticasone furoate)	GlaxoSmithKline	OTC	ST
flunisolide	Various		
fluticasone propionate	Various		
Nasacort Allergy 24 HR (trimamcinolone acetonide)	Sanofi	OTC	ST
Nasonex (mometasone furoate monohydrate)	Merck Sharp Dohme	FDA-approved management of nasal polyps	ST
Omnaris (ciclesonide)	Sunovion		ST
Qnasl (beclomethasone dipropionate)	Teva	dry nasal aerosol	ST
Rhincort Allergy (budesonide)	McNeil	OTC	ST
Rhincort Aqua (budesonide)	AstraZeneca		ST
triamcinolone	Various		
Ticalast (ciclesonide)	Shoreline Pharm		ST
Veramyst (fluticasone furoate)	GlaxoSmithKline	Withdrawn mkt	ST
Zetonna (ciclesonide)	Sunovion	dry nasal aerosol	ST
Xhance (fluticasone propionate)	OptiNose	FDA-approved management of nasal polyps	P&T 12/2017

References

1. Xhance [package insert]. Yardley, PA: OptiNose US, Inc; September 2017
2. Clinical Pharmacology [online database]. Tampa, FL: Elsevier / Gold Standard, Inc. 2017. Available at www.clinicalpharmacology-ip.com. Accessed on November, 2017.
3. Lexicomp Online, Hudson, Ohio; Lexi-Comp, Inc.; 2017. Available at <http://online.lexi.com>. Accessed on November 2017.
4. Intranasal Corticosteroids Therapeutic Class Overview, OptumRx. Accessed on November, 2017